SPONSORED: Multidisciplinary Cancer Care Through Virtual Collaboration

The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.

The selective ROCK2 inhibitor TDI01 generated organ-wide responses in previously treated moderate-to-severe chronic graft-versus-host disease, with the 400-mg dose performing best.

The FDA approved rusfertide for the treatment of patients with polycythemia vera.

Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.

The phase 3 DAWN-303 trial is evaluating the oral KRAS G12D inhibitor INCB161734 in previously untreated, KRAS G12D–mutated metastatic PDAC.

Richard K. and Nancy K. Lubin have made a $35 million gift to Dana-Farber Cancer Institute’s Future of Cancer Care Fund.

Dosing adjustments of ponatinib based on responses increased tolerability in patients with chronic myeloid leukemia according to OPTIC.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.